drugset / Trial / NCT01878825

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older

NCT01878825

Phase 3 Completed 121 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of Fluviral™ containing the influenza strains recommended for the 2013-2014 season in adults aged 18 years and older.

Timeline

Start
2013-07-18
Primary completion
2013-08-09
Completion
2013-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluviral Vaccine Intramuscular

Indications